Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T
Go back to Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T| (NASDAQ: ROIV) | Delayed: 38.22 -0.77 (1.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.99 | 52 Week High | $ | |||
| Open | $38.73 | 52 Week Low | $ | |||
| Day High | $39.17 | P/E | N/A | |||
| Day Low | $38.11 | EPS | $ | |||
| Volume | 6,752,730 | |||||
